GSRGT 2020: Management of Chemotherapy-Resistant Germ Cell Tumors in 2020
(Urotoday.com) To kick-off a series of lectures discussing testicular cancer at the inaugural meeting of the Global Society of Rare Genitourinary Tumors (GSRGT) 2020 virtual summit, Dr. Andrea Necchi provided the keynote lecture discussing the management of chemotherapy-resistant germ cell tumors. Dr. Necchi started by highlighting the global incidence and mortality of germ-cell tumors:
As follows is an overview of first- and subsequent salvage treatment options:
10-20% of patients will progress/relapse after first-line therapy
A proportion varying from 25% to 60-70% of patients with will be cured by second-line treatments
There are very few randomized trials to guide treatment decisions
GSRGT 2020: Management of Chemotherapy Resistant Germ Cell Tumors in 2020 - Keynote Commentary
(Urotoday.com) To provide a context to the keynote lecture by Dr. Andrea Necchi discussing the management of chemotherapy-resistant germ cell tumors at the inaugural Global Society of Rare Genitourinary Tumors virtual summit, Dr. Lucia Nappi provided a commentary discussion of this topic. By way of background, Dr. Nappi notes that 20-30% of patients will relapse after first-line therapy, and the prognosis after second-line therapy is less favorable, with only 15-30% of patients maintaining a continued disease-free rate. Most studies in this disease space are non-randomized, small, and include a heterogeneous population. Very few randomized studies have shown a higher benefit of sequential salvage high-dose chemotherapy than a single consolidating high-dose chemotherapy cycle after three standard doses. Furthermore, there is a lack of clinical/biological predictive markers for appropriate
GSRGT 2020: Penile Cancer: Conservative N-strategies - Minimally Invasive Staging of the Groin
(Urotoday.com) The penile cancer session at the inaugural virtual summit of the Global Society of Rare Genitourinary Tumors (GSRGT) included a presentation of conservative strategies for lymph node management, including minimally invasive staging of the groin, by Dr. Oscar Brouwer from The Netherlands Cancer Institute. Dr. Brouwer notes that penile cancer survival is highly dependent on lymph node status and that appropriate management of the regional lymph nodes is crucial for patient survival. Older studies suggest that early resection of occult metastasis versus resection after the disease is palpable during surveillance significantly improves cancer-specific survival (84% vs 35% at 3 years). As such, detecting lymphatic spread as early as possible is crucial. Dr. Brouwer notes that if there are palpable abnormalities of the groin, there is no place for a trial of antibiotics and clin